Bleximenib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.
Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367442581 under CC BY-SA 4.0; modifications have been made.